Genetic variants increase the risk of osteonecrosis in children under age 10 with acute lymphoblastic leukemia.
Acute Lymphoblastic Leukemia
Researchers have identified a genetic variant, 2R thymidylate synthase polymorphism, that is associated with an increased risk for avascular necrosis in children with ALL.
PEG-asparaginase had both similar safety and efficacy to intramuscular native E coli l-asparaginase for the treatment of children with ALL in complete remission.
The combination of chemotherapy with the TKI ponatinib was an effective treatment for patients with newly diagnosed Ph-positive acute lymphoblastic leukemia.
Even in the absence of cranial radiation therapy, survivors of childhood acute lymphoblastic leukemia (ALL) have decreased neurocognitive function years later.
A single cycle of blinatumomab resulted in complete minimal residual disease response in 78% of patients with acute lymphoblastic leukemia.
The FDA has approved blinatumomab (Blincyto) for the treatment of patients with Philadelphia chromosome-negative precursor B-cell acute lymphoblastic leukemia.
Treatment of Adult Acute Lymphoblastic Leukemia (ALL) With a Focus on Emerging Investigational and Targeted Therapies
In this review, we will discuss the management of ALL in the adult population, in the context of the recently published guidelines from the NCCN. We will focus in particular on the strides being made in salvage and targeted approaches.
The US Food and Drug Administration has approved asparaginase Erwinia chrysanthemi for the treatment of patients with acute lymphoblastic leukemia, who have developed hypersensitivity to E. coli derived asparaginase and pegaspargase chemotherapy.
We have witnessed remarkable gains in the biological understanding and treatment of acute lymphoblastic leukemia (ALL) over the past decade.